AstraZeneca neurofibromatosis treatment gets orphan drug designation in Japan
AstraZeneca said on Tuesday that selumetinib, its treatment for genetic disease neurofibromatosis type 1, has been granted orphan drug designation in Japan.
Selumetinib is co-developed and co-commercialised with Merck Co.
José Baselga, executive vice president of Oncology R&D at AstraZeneca, said: "Neurofibromatosis type 1 can have a devastating impact on children and new medicines are urgently needed to help treat the resulting plexiform neurofibromas and associated clinical issues.
"Current options in most countries are limited and this designation is a significant step forward in bringing the first medicine for NF1 to paediatric patients in Japan."
The Japanese Ministry of Health, Labour and Welfare grants organ drug designation to medicines intended for the treatment of diseases that affect fewer than 50,000 patients in Japan and for which there is a high unmet medical need.
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news articles and we may not share the views of the author. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.